A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.

MLA

Feldman, Steven R., et al. “A Randomized, Double-Blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate-to-Severe Plaque Psoriasis.” Journal of the American Academy of Dermatology, vol. 91, no. 3, Sept. 2024, pp. 440–47. EBSCOhost, https://doi.org/10.1016/j.jaad.2024.04.045.

APA

Feldman, S. R., Narbutt, J., Girolomoni, G., Brzezicki, J., Reznichenko, N., Zegadło-Mylik, M. A., Pulka, G., Dmowska-Stecewicz, M., Kłujszo, E., Rekalov, D., Rajzer, L., Lee, J., Lee, M., & Rho, Y. H. (2024). A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology, 91(3), 440–447. https://doi.org/10.1016/j.jaad.2024.04.045

Chicago

Feldman, Steven R, Joanna Narbutt, Giampiero Girolomoni, Jan Brzezicki, Nataliya Reznichenko, Maria Agnieszka Zegadło-Mylik, Grazyna Pulka, et al. 2024. “A Randomized, Double-Blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate-to-Severe Plaque Psoriasis.” Journal of the American Academy of Dermatology 91 (3): 440–47. doi:10.1016/j.jaad.2024.04.045.